Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
(NASDAQ:VERU), — Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA — — Incremental weight loss is an acceptable approvable primary endpoint with key secondary endpoints on physical function and body composition improvements — — Company plans to initiate Phase 2 […]